Anti-CD20 Therapies Shown to be Effective After Switch From Natalizumab
Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.
Source: ajmc.com